Emboshield

Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009

...ar products - Self-expanding and balloon-expanding peripheral stents, including the Absolute Pro and Omnilink Elite Peripheral Stent Systems, and the emboshield Nav6 Embolic Protection Device for carotid stenting. ...

Abbott Announces Launch of Next-Generation Embolic Protection System

... emboshield NAV6(TM) Demonstrates Abbott's Continued Leadershi...today announced the launch of the sixth-generation emboshield NAV6(TM) Embolic Protection System for use in caro...brain, potentially causing an ischemic stroke. The emboshield NAV6 is now available in the United States and Eur...

Abbott Announces EuroPCR 2009 Activities

... vessel closure device with this indication in the European Union. emboshield Nav6 : Abbott will feature its sixth-generation Emboshield(R) NAV6 Embolic ...e brain, potentially causing an ischemic stroke. The advanced design of the emboshield NAV6 offers simpler procedure preparation and excellent deliverability and ...

Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009

...ar products - Self-expanding and balloon-expanding peripheral stents, including the Absolute Pro and Omnilink Elite Peripheral Stent Systems, and the emboshield Nav6 Embolic Protection Device for carotid stenting. ...

Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease

...cular pipeline include: the Omnilink Elite(TM) Peripheral Stent System; the emboshield NAV6(TM) Embolic Protection System for carotid stenting; a fully bioabsorba...market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System. emboshield NAV6 is pending 510(k) clearance by the United States Food and Drug Adminis...

Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery

...d ACCUNET(TM) Embolic Protection System. The EXACT study included 2,124 patients and utilized Abbott's Xact(R) Rapid Exchange Carotid Stent System and emboshield BareWire(TM) Rapid Exchange Embolic Protection System. The key objective of both trials was to determine whether carotid stenting could be performed s...

Emboshield in Medical Technology

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

...cular pipeline include: the Omnilink Elite(TM) Peripheral Stent System; the emboshield NAV6(TM) Embolic Protection System for carotid stenting; and the XIENCE PRI...XIENCE V(R) Everolimus Eluting Coronary Stent System. Onmilink Elite, emboshield NAV6 and XIENCE PRIME are investigational devices and are not available for...

Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiology's 56th Annual Scientific Session

...alties in real-world (non-clinical trial) settings in patients who are at high risk for carotid artery surgery. Clinical outcome data for Abbott's emboshield BareWire(TM) Rapid Exchange Embolic Protection System and Xact Rapid Exchange Carotid Stent System and ACCULINK(TM) Carotid Stent System and ACCUN...

Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke

...luates Next-Generation Embolic Protection Device Abbott's next-generation emboshield PRO(TM) Embolic Protection System, currently available in Europe, is under ...ort a 510(k) application to the U.S. Food and Drug Administration (FDA) for emboshield PRO. About Carotid Artery Disease and Stroke Stroke is the third leadin...

Emboshield in Medical Products

Xact Carotid Stent

Description:...he Xact stent is designed for use in combination with the fully retractable emboshield filter. emboshield is designed to capture emboli that can break off during a carotid stenting ...
Company:Abbott Vascular

Emboshield in Biological News

2 carotid artery stenting studies show results comparable to AHA guidelines

...d ACCUNET(tm) Embolic Protection System. The EXACT study included 2,124 patients and utilized Abbott's Xact(r) Rapid Exchange Carotid Stent System and emboshield BareWire(tm) Rapid Exchange Embolic Protection System. The key objective of both trials was to determine whether carotid stenting could be performed s...